Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2021 Apr 1;86(4):e97–e105. doi: 10.1097/QAI.0000000000002583

Table 1:

Descriptive characteristics of HIV-positive* HIV Prevention Survey participants, by round

Round 1
(Apr 2014-
Apr 2015)
Round 2
(May-Dec
2015)
Round 3
(May-Dec
2016)
Round 4
(Mar-Nov
2017)
Round 5
(Apr 2018-
Mar 2019)
Variable N % N % N % N % N %
Total 758 807 1331 1065 946
Gender
   Male 200 26.4 155 19.2 223 16.8 212 19.9 150 15.9
   Female 558 73.6 652 80.8 1108 83.2 853 80.1 796 84.1
Age
  15-24 89 11.7 103 12.8 155 11.6 115 10.8 108 11.4
  25-34 253 33.4 259 32.1 361 27.1 292 27.4 266 28.1
  35-44 244 32.2 231 28.6 453 34.0 356 33.4 302 31.9
  45-59 172 22.7 214 26.5 362 27.2 302 28.4 270 28.5
Marital status
  Single 61 8.0 127 15.7 299 22.5 145 13.6 136 14.4
  Married or living together 501 66.1 501 62.1 780 58.6 652 61.2 556 58.8
  Divorced/separated/widowed 196 25.9 179 22.2 249 18.7 268 25.2 253 26.7
Urbanicity
  Rural 415 54.7 525 65.1 907 68.1 715 67.1 616 65.1
  Urban 344 45.3 282 34.9 424 31.9 350 32.9 330 34.9
CD4 cell count
  <200/μL 81 12.1 91 15.5 184 17.7 85 10.8 70 9.1
  200-<350/μL 140 20.9 114 19.5 218 21.0 131 16.7 122 15.8
  350-500/μL 150 22.4 120 20.5 222 21.4 178 22.6 156 20.2
  >500/μL 299 44.6 261 44.6 413 39.8 392 49.9 423 54.9
*

The total number of participants surveyed and analyzed (regardless of HIV status) was 3,034 in R1, 3,160 in R2, 5,089 in R3, 4,424 in R4, and 4,086 in R5 (see Figure 1)

not all HPS participants had a blood sample taken or were successfully tested for CD4